Skip to main content

TGM2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 7.

Be the first to review this product! Submit a review

Images

Western blot - Human TGM2 (Transglutaminase 2) knockout HeLa cell line (AB265245), expandable thumbnail
  • Sanger Sequencing - Human TGM2 (Transglutaminase 2) knockout HeLa cell line (AB265245), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 7

Alternative names

ALPHA SUBUNIT, C polypeptide, EC 2.3.2.13, G alpha h, GNAH, GNAH G PROTEIN, G[a]h, Gh CLASS G ALPHA h, H POLYPEPTIDE, HEL-S-45, Protein-glutamine gamma-glutamyltransferase 2, TG 2, TG(C), TGC, TGC GUANINE NUCLEOTIDE BINDING PROTEIN, TGM2_HUMAN, TGase C, TGase H, TGase-2, TgaseII, Tissue transglutaminase, Transglutaminase 2 C polypeptide, Transglutaminase C, Transglutaminase H, Transglutaminase-2, epididymis secretory protein Li 45, tTG, tTGas

Recommended products

TGM2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 7.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 7
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
TGM2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Transglutaminase 2 also known as TG2 or tissue transglutaminase is an enzyme with a mass of approximately 74 kDa. It catalyzes the formation of covalent bonds by crosslinking glutamine residues and lysine residues in proteins. This enzyme is widely expressed in various tissues including the liver heart and lungs. It can act as a GTPase a kinase and a protein disulfide isomerase highlighting its multifunctional nature. Additionally transglutaminase 2 associates with cell membranes cytoskeleton and extracellular matrix indicating its versatile involvement in cellular processes.

Biological function summary

Transglutaminase 2 plays roles in cell adhesion wound healing and the immune response. It mediates extracellular matrix stabilization through crosslinking structural proteins which is critical for tissue repair. The enzyme does not typically form a stable part of a large complex but interacts with fibronectin as a binding partner highlighting its role in cellular adhesion and migration. The enzymatic activity of transglutaminase 2 helps maintain tissue integrity by modifying extracellular and intracellular proteins.

Pathways

Transglutaminase 2 contributes significantly to the integrin-mediated signaling pathway and the apoptosis pathway. It assists in the modulation of cell-matrix interactions by crosslinking matrix proteins which is important for integrin signaling. During apoptosis transglutaminase 2 promotes cellular processes that lead to cell death via its involvement in nuclear condensation and DNA fragmentation. In these pathways proteins such as fibronectin and integrins interact with transglutaminase 2 facilitating its regulatory functions.

Associated diseases and disorders

Transglutaminase 2 is associated with celiac disease and neurodegenerative disorders like Huntington's disease. Its autoantigenic properties make it a target in celiac disease where antibodies against transglutaminase 2 play a role in the pathology by affecting intestinal tissue. In Huntington's disease transglutaminase 2 contributes to the formation of protein aggregates which are toxic to neurons. This enzyme's interactions with proteins such as gliadin in celiac disease and huntingtin in Huntington's disease are central to its pathogenic mechanism.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com